ABSTRACT
BACKGROUND: Each year, approximately 1.1 million children are exposed in utero to human immunodeficiency virus antiretrovirals, yet their safety is often not well characterized during pregnancy. The Tsepamo study reported a neural tube defect signal in infants exposed to the integrase strand transfer inhibitor (InSTI) dolutegravir from conception, suggesting that exposure during early fetal development may be detrimental. METHODS: The effects of InSTIs on 2 human embryonic stem cell (hESC) lines were characterized with respect to markers of pluripotency, early differentiation, and cellular health. In addition, fetal resorptions after exposure to InSTIs from conception were analyzed in pregnant mice. RESULTS: At subtherapeutic concentrations, second-generation InSTIs bictegravir, cabotegravir, and dolutegravir decreased hESC counts and pluripotency and induced dysregulation of genes involved in early differentiation. At therapeutic concentrations, bictegravir induced substantial hESC death and fetal resorptions. It is notable that first-generation InSTI raltegravir did not induce any hESC toxicity or differentiation, at any concentration tested. CONCLUSIONS: Exposure to some InSTIs, even at subtherapeutic concentrations, can induce adverse effects in hESCs and pregnant mice. Given the increasingly prevalent use of second-generation InSTIs, including in women of reproductive age, it is imperative to further elucidate the effect of InSTIs on embryonic development, as well as their long-term safety after in utero exposure.
Subject(s)
HIV Infections , HIV Integrase Inhibitors , Human Embryonic Stem Cells , Maternal Exposure , Animals , Female , Humans , Mice , Pregnancy , Drug Resistance, Viral/genetics , Fetal Resorption/chemically induced , Fetal Resorption/drug therapy , Heterocyclic Compounds, 3-Ring/toxicity , Heterocyclic Compounds, 4 or More Rings/pharmacology , HIV Infections/drug therapy , HIV Integrase Inhibitors/toxicity , Human Embryonic Stem Cells/metabolism , Pyridones/therapeutic use , Raltegravir Potassium/toxicity , Infant, NewbornABSTRACT
Dolutegravir (DTG) is currently one of the most used Integrase inhibitors (INI) in antiretroviral therapies (ARV) in both naïve and experienced people living with HIV (PLWHIV). We analyzed a multicenter cohort of PLWHIV, both naïve and experienced, starting an ARV including DTG. We enrolled 3775 PLWHIV: 2763 (73.2%) were males, with a median age of 50 years. During 9890.7 PYFU, we observed 930 discontinuations (9.4 per 100 PYFU). Estimated probabilities of maintaining DTG at three and five years were 75.1% and 67.2%, respectively. Treatment-naïve pts showed a lower probability of maintaining DTG at three and five years compared to treatment-experienced PLWHIV (log-rank p < 0.001). At a multivariate analysis, a longer time of virological suppression (aHR 0.994, p < 0.001) and having experienced a previous virological failure (aHR 0.788, p = 0.016) resulted protective against DTG discontinuation. Most discontinuations (84.0%) happened within the first 12 months of DTG initiation, in particular, 92.2% of discontinuations due to neuropsychiatric toxicity were observed in the first year. Our data confirm the overall good tolerability of DTG in clinical practice, with a low rate of discontinuations. CNS toxicity resulted the main reason for DTG discontinuation, with most related interruptions happening in the first year from DTG introduction.
Subject(s)
Drug Tolerance , HIV Infections/drug therapy , HIV Integrase Inhibitors/toxicity , Heterocyclic Compounds, 3-Ring/toxicity , Oxazines/toxicity , Piperazines/toxicity , Pyridones/toxicity , Adult , Anti-HIV Agents/therapeutic use , Anti-HIV Agents/toxicity , Cohort Studies , Female , HIV Infections/epidemiology , Heterocyclic Compounds, 3-Ring/therapeutic use , Humans , Italy/epidemiology , Male , Middle Aged , Oxazines/therapeutic use , Piperazines/therapeutic use , Pyridones/therapeutic useABSTRACT
Dolutegravir (DTG) is an antiretroviral drug of the integrase strand transfer inhibitor (INSTI) class used to treat human immunodeficiency virus infection. It is the recommended first-line regimen for most people, including women of childbearing age. However, some human and animal studies have suggested that DTG causes birth defects, although its developmental toxicity remains controversial. Here, we investigated the adverse effects of DTG using pluripotent stem cell-based in vitro morphogenesis models that have previously been validated as effective tools to assess the developmental toxicity of various chemicals. DTG diminished the growth and axial elongation of the morphogenesis model of mouse pluripotent stem cells at exposures of 2 µM and above in a concentration-dependent manner. Concomitantly, DTG altered the expression profiles of developmental regulator genes involved in embryonic patterning. The adverse effects were observed when the morphogenesis model was exposed to DTG at early stages of development, but not at later stages. The potency and molecular impact of DTG on the morphogenesis model were distinct from other INSTIs. Last, DTG altered the growth and gene expression profiles of the morphogenesis model of human embryonic stem cells at 1 µM and above. These studies demonstrate that DTG impairs morphological and molecular aspects of the in vitro morphogenesis models in a manner dependent on dose and timing of exposure through mechanisms that are unrelated to its action as an INSTI. This finding will be useful for interpreting the conflicting outcomes regarding the developmental toxicity of DTG in human and animal studies.
Subject(s)
HIV Integrase Inhibitors , Animals , Female , HIV Integrase Inhibitors/therapeutic use , HIV Integrase Inhibitors/toxicity , Heterocyclic Compounds, 3-Ring/toxicity , Humans , Mice , Morphogenesis , Oxazines , Piperazines , Pyridones , Stem CellsABSTRACT
BACKGROUND: An in vitro rat whole embryo culture study investigated whether direct exposure to dolutegravir (TivicayTM ) during the critical period for neural tube development would result in abnormal development. METHODS: Dolutegravir (DTG), and HIV integrase inhibitor, was administered at 0 (vehicle), 5.3 µg/mL and 9.3 µg/mL on Gestation Day (GD) 9 through 11 (approximate 40 hour exposure period) along with positive (Valproic Acid) and negative (Penicillin G) controls. The DTG concentrations tested were selected based on clinical exposure at the maximum human recommended dose and maximum feasible concentration that could be formulated under the experimental conditions. RESULTS: Approximately 6% of DTG present in the culture media was absorbed into the embryos, demonstrating embryonic exposure at a similar level to that observed in a rat DTG placental transfer study. There was no effect in either the DTG or Penicillin G groups on visceral yolk sac size/morphology, embryo size, somite number and embryo morphology at any concentration tested. Valproic Acid, by contrast, produced statistically significant decreases in visceral yolk sac size, embryo size and somite number along with defects in visceral yolk sac and embryonic morphology, including neural tube defects (NTDs), in all embryos. CONCLUSION: DTG at the maximum human recommended dose administered to rats in a whole embryo culture assay did not produce any abnormal effects, while the positive control Valproic Acid produced abnormal effects, including neural tube defects.
Subject(s)
Neural Tube Defects , Placenta , Animals , Embryo, Mammalian , Female , Heterocyclic Compounds, 3-Ring/toxicity , Oxazines , Piperazines , Pregnancy , Pyridones , RatsABSTRACT
Dolutegravir (DTG) is a first-line antiretroviral drug (ARV) used in combination therapy for the treatment of human immunodeficiency virus type-1 (HIV-1) infection. The drug is effective, safe, and well tolerated. Nonetheless, concerns have recently emerged for its usage in pregnant women or those of child-bearing age. Notably, DTG-based ARV regimens have been linked to birth defects seen as a consequence of periconceptional usages. To this end, uncovering an underlying mechanism for DTG-associated adverse fetal development outcomes has gained clinical and basic research interest. We now report that DTG inhibits matrix metalloproteinases (MMPs) activities that could affect fetal neurodevelopment. DTG is a broad-spectrum MMPs inhibitor and binds to Zn++ at the enzyme's catalytic domain. Studies performed in pregnant mice show that DTG readily reaches the fetal central nervous system during gestation and inhibits MMP activity. Postnatal screenings of brain health in mice pups identified neuroinflammation and neuronal impairment. These abnormalities persist as a consequence of in utero DTG exposure. We conclude that DTG inhibition of MMPs activities during gestation has the potential to affect prenatal and postnatal neurodevelopment.
Subject(s)
Anti-Retroviral Agents/toxicity , Heterocyclic Compounds, 3-Ring/toxicity , Matrix Metalloproteinase Inhibitors/toxicity , Neural Tube Defects/chemically induced , Neurodevelopmental Disorders/chemically induced , Neuroinflammatory Diseases/chemically induced , Oxazines/toxicity , Piperazines/toxicity , Pyridones/toxicity , Animals , Anti-Retroviral Agents/pharmacokinetics , Anti-Retroviral Agents/pharmacology , Brain/embryology , Brain/enzymology , Catalytic Domain/drug effects , Female , Gene Expression Profiling , Heterocyclic Compounds, 3-Ring/pharmacokinetics , Heterocyclic Compounds, 3-Ring/pharmacology , Male , Matrix Metalloproteinase Inhibitors/pharmacokinetics , Matrix Metalloproteinase Inhibitors/pharmacology , Mice , Mice, Inbred C3H , Molecular Docking Simulation , Neural Tube Defects/embryology , Neuroimaging , Neuroinflammatory Diseases/embryology , Oxazines/pharmacokinetics , Oxazines/pharmacology , Piperazines/pharmacokinetics , Piperazines/pharmacology , Placenta/chemistry , Pregnancy , Pyridones/pharmacokinetics , Pyridones/pharmacology , Tissue Distribution , Zinc/metabolismABSTRACT
Development of proteolysis targeting chimeras (PROTACs) is emerging as a promising strategy for targeted protein degradation. However, the drug development using the heterobifunctional PROTAC molecules is generally limited by poor membrane permeability, low in vivo efficacy and indiscriminate distribution. Herein an aptamer-PROTAC conjugation approach was developed as a novel strategy to improve the tumor-specific targeting ability and in vivo antitumor potency of conventional PROTACs. As proof of concept, the first aptamer-PROTAC conjugate (APC) was designed by conjugating a BET-targeting PROTAC to the nucleic acid aptamer AS1411 (AS) via a cleavable linker. Compared with the unmodified BET PROTAC, the designed molecule (APR) showed improved tumor targeting ability in a MCF-7 xenograft model, leading to enhanced in vivo BET degradation and antitumor potency and decreased toxicity. Thus, the APC strategy may pave the way for the design of tumor-specific targeting PROTACs and have broad applications in the development of PROTAC-based drugs.
Subject(s)
Antineoplastic Agents/therapeutic use , Aptamers, Nucleotide/therapeutic use , Breast Neoplasms/drug therapy , Oligodeoxyribonucleotides/therapeutic use , Proteolysis/drug effects , Animals , Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/toxicity , Aptamers, Nucleotide/chemical synthesis , Aptamers, Nucleotide/toxicity , Cell Cycle Proteins/antagonists & inhibitors , Cell Cycle Proteins/metabolism , Cell Line, Tumor , Disulfides/chemical synthesis , Disulfides/therapeutic use , Disulfides/toxicity , Heterocyclic Compounds, 3-Ring/chemical synthesis , Heterocyclic Compounds, 3-Ring/therapeutic use , Heterocyclic Compounds, 3-Ring/toxicity , Humans , Mice , Oligodeoxyribonucleotides/chemical synthesis , Oligodeoxyribonucleotides/toxicity , Proof of Concept Study , Pyrrolidines/chemical synthesis , Pyrrolidines/therapeutic use , Pyrrolidines/toxicity , Transcription Factors/antagonists & inhibitors , Transcription Factors/metabolism , Xenograft Model Antitumor AssaysABSTRACT
Diphlorethohydroxycarmalol (DPHC), a type of phlorotannin isolated from the marine alga Ishige okamurae, reportedly alleviates impaired glucose tolerance. However, the molecular mechanisms of DPHC regulatory activity and by which it exerts potential beneficial effects on glucose transport into skeletal myotubes to control glucose homeostasis remain largely unexplored. The aim of this study was to evaluate the effect of DPHC on cytosolic Ca2+ levels and its correlation with blood glucose transport in skeletal myotubes in vitro and in vivo. Cytosolic Ca2+ levels upon DPHC treatment were evaluated in skeletal myotubes and zebrafish larvae by Ca2+ imaging using Fluo-4. We investigated the effect of DPHC on the blood glucose level and glucose transport pathway in a hyperglycemic zebrafish. DPHC was shown to control blood glucose levels by accelerating glucose transport; this effect was associated with elevated cytosolic Ca2+ levels in skeletal myotubes. Moreover, the increased cytosolic Ca2+ level caused by DPHC can facilitate the Glut4/AMPK pathways of the skeletal muscle in activating glucose metabolism, thereby regulating muscle contraction through the regulation of expression of troponin I/C, CaMKII, and ATP. Our findings provide insights into the mechanism of DPHC activity in skeletal myotubes, suggesting that increased cytosolic Ca2+ levels caused by DPHC can promote glucose transport into skeletal myotubes to modulate blood glucose levels, thus indicating the potential use of DPHC in the prevention of diabetes.
Subject(s)
Calcium/metabolism , Glucose/metabolism , Heterocyclic Compounds, 3-Ring/pharmacology , Muscle, Skeletal/metabolism , Phaeophyceae/chemistry , Animals , Biological Transport/drug effects , Blood Glucose/metabolism , Cell Line , Cell Survival/drug effects , Cytosol/metabolism , Glucose Transporter Type 4/metabolism , Heterocyclic Compounds, 3-Ring/toxicity , Larva/drug effects , Larva/metabolism , Muscle Contraction/drug effects , Muscle Fibers, Skeletal/drug effects , Muscle Fibers, Skeletal/metabolism , Signal Transduction/drug effects , ZebrafishABSTRACT
Strigolactone (SL) is a plant hormone that can improve plant stress resistance by regulating physiological processes and gene expression. GR24 is a synthetic strigolactone, which can also be used as a plant growth regulator. In this paper, the effects of exogenous GR24 on the growth and development of rape (Brassica rapa L.) under low temperature (4 °C) were studied. The results showed that low temperature (4 °C) inhibited the growth of rape seedlings, and exogenous GR24 significantly alleviated the effect of low temperature stress on rape seedlings. Compared with 4 °C treatment, GR24 + 4 °C treatment can increase the cell viability, soluble protein and proline content, enhance antioxidant enzyme activity, inhibit the production of reactive oxygen species (ROS), improve photosynthesis, and reduce the relative conductivity of rape seedlings. Further research shows that H2O2 plays a central role in improving the cold resistance of rape seedlings by GR24. qRT-PCR results indicated that GR24 significantly increased the expression of genes. Mainly includes antioxidant enzyme genes, nicotinamide adenine dinucleotide phosphate (NADPH) oxidase genes, mitogen-activated protein kinase (MAPK) genes and cold-regulated genes. These results indicate that GR24 improves the cold tolerance of plants by regulating the expression of related genes. RNA-seq analysis revealed that there were 152 differentially expressed genes (DGEs) in T (4 °C)_vs_ST (GR24 + 4 °C), including 100 up-regulated genes and 52 down-regulated genes. These DEGs play an important role in carbon metabolism pathway, oxidative phosphorylation pathway, antioxidant activity and photosynthesis pathways. We selected 11 differentially expressed genes for qRT-PCR verification, and the verification results were consistent with RNA-seq results.
Subject(s)
Brassica rapa/physiology , Cold Temperature , Hydrogen Peroxide/metabolism , Seedlings/physiology , Stress, Physiological , Gene Expression Regulation, Plant , Genes, Plant , Heterocyclic Compounds, 3-Ring/toxicity , Lactones/toxicityABSTRACT
The combination of drugs targeting Ral and PI3K/AKT signaling has antitumor efficacy in preclinical models of pancreatic cancer. We combined dinaciclib (small molecule cyclin dependent kinase inhibitor with MK-2206 (Akt inhibitor) in patients with previously treated/metastatic pancreatic cancer. Patients were treated with dinaciclib (6-12 mg/m2 i.v.) and MK-2206 (60-135 mg p.o.) weekly. Tumor biopsies were performed to measure pAKT, pERK, and Ki67 at baseline and after one completed cycle (dose level 2 and beyond). Thirty-nine patients participated in the study. The maximum tolerated doses were dinaciclib 9 mg/m2 and MK-2206 135 mg. Treatment-related grade 3 and 4 toxicities included neutropenia, lymphopenia, anemia, hyperglycemia, hyponatremia, and leukopenia. No objectives responses were observed. Four patients (10%) had stable disease as their best response. At the recommended dose, median survival was 2.2 months. Survival rates at 6 and 12 months were 11% and 5%, respectively. There was a nonsignificant reduction in pAKT composite scores between pretreatment and post-treatment biopsies (mean 0.76 vs. 0.63; P = 0.635). The combination of dinaciclib and MK-2206 was a safe regimen in patients with metastatic pancreatic cancer, although without clinical benefit, possibly due to not attaining biologically effective doses. Given the strong preclinical evidence of Ral and AKT inhibition, further studies with better tolerated agents should be considered.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/toxicity , Carcinoma, Pancreatic Ductal/drug therapy , Cyclic N-Oxides/toxicity , Heterocyclic Compounds, 3-Ring/toxicity , Indolizines/toxicity , Pancreatic Neoplasms/drug therapy , Protein Kinase Inhibitors/toxicity , Pyridinium Compounds/toxicity , Administration, Oral , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Biopsy , Carcinoma, Pancreatic Ductal/diagnosis , Carcinoma, Pancreatic Ductal/mortality , Carcinoma, Pancreatic Ductal/pathology , Cyclic N-Oxides/administration & dosage , Female , Heterocyclic Compounds, 3-Ring/administration & dosage , Humans , Indolizines/administration & dosage , Male , Maximum Tolerated Dose , Middle Aged , Neoplasm Staging , Pancreas/drug effects , Pancreas/pathology , Pancreatic Neoplasms/diagnosis , Pancreatic Neoplasms/mortality , Pancreatic Neoplasms/pathology , Protein Kinase Inhibitors/administration & dosage , Pyridinium Compounds/administration & dosage , Survival Rate , Treatment OutcomeABSTRACT
Despite the availability of modern antiretroviral therapy (ART), neurocognitive impairment persists among some persons with HIV (PWH). We investigated the role of exposure to four major classes of ARTs in neurocognitive impairment in PWH. A single-site cohort of 343 PWH was recruited. Lifetime ART medication history was obtained from medical health records. We evaluated the role of ART exposure as a predictor of neurocognitive impairment using univariate analyses and machine learning, while accounting for potential effects of demographic, clinical, and comorbidity-related risk factors. Out of a total of 26 tested variables, two random forest analyses identified the most important characteristics of a neurocognitively impaired group (N = 59): Compared with a neurocognitively high-performing group (N = 132; F1-score = 0.79), we uncovered 13 important risk factors; compared with an intermediate-performing group (N = 152; F1-score = 0.75), 16 risk factors emerged. Longer lifetime ART exposure, especially to integrase inhibitors, was one of the most important predictors of neurocognitive impairment in both analyses (rank 2 of 13 and rank 4 of 16, respectively), superseding effects of age (rank 11/13, rank 15/16) and HIV duration (rank 13/13, rank 16/16). Concerning specific integrase inhibitors, the impaired group had significantly longer dolutegravir exposure (p = 0.011) compared with the high-performing group (p = 0.012; trend compared with the intermediate group p = 0.063). A longer duration to integrase inhibitor intake was negatively related to cognition in this cohort. Our findings suggest that possible cognitive complications of long-term exposure to integrase inhibitors, in particular dolutegravir, should be closely monitored in PWH.
Subject(s)
Anti-HIV Agents/toxicity , Central Nervous System/drug effects , Cognitive Dysfunction/chemically induced , HIV Infections/drug therapy , HIV Protease Inhibitors/toxicity , Heterocyclic Compounds, 3-Ring/toxicity , Oxazines/toxicity , Piperazines/toxicity , Pyridones/toxicity , Reverse Transcriptase Inhibitors/toxicity , Adult , Antiretroviral Therapy, Highly Active/methods , Central Nervous System/pathology , Central Nervous System/virology , Cognitive Dysfunction/pathology , Cognitive Dysfunction/prevention & control , Cognitive Dysfunction/virology , Cohort Studies , Depression/physiopathology , Female , HIV Infections/pathology , HIV Infections/virology , Humans , Machine Learning , Male , Mental Disorders/physiopathology , Middle Aged , Neuropsychological Tests , Risk Factors , Suicidal IdeationABSTRACT
The discovery of new, safe, and effective pesticides is one of the main means for modern crop protection and parasitic disease control. During the search for new insecticidal secondary metabolites from endophytes in Stemona sessilifolia (a traditional Chinese medicine with a long history as an insecticide), 10 new insecticidal endostemonines A-J (1-10) were identified from an endophytic Streptomyces sp. BS-1. Their structures were determined by comprehensive spectroscopic analysis. Endostemonines A-J represent the first reported naturally occurring pyrrole-2-carboxylic ester derivatives, which consisted of different fatty acid chains at the C-2 of pyrrole ring were produced by traditional Chinese medicine endophytic microbes. All new tested compounds exhibited strong lethal activity against Aphis gossypii (LC50 value range of 3.55-32.00 mg/L after 72 h). This research highlighted the discovery of pesticide natural products from insecticidal medicinal plant endophytes for the first time, paving a new pathway for the development of pest control.
Subject(s)
Endophytes/chemistry , Heterocyclic Compounds, 3-Ring/metabolism , Insecticides/metabolism , Stemonaceae/microbiology , Streptomyces/chemistry , Streptomyces/metabolism , Animals , Aphids/drug effects , Endophytes/metabolism , Heterocyclic Compounds, 3-Ring/chemistry , Heterocyclic Compounds, 3-Ring/toxicity , Insecticides/chemistry , Insecticides/toxicity , Secondary MetabolismABSTRACT
OBJECTIVE: Maternal folate (vitamin B9) status is the largest known modifier of neural tube defect risk, so we evaluated folate-related mechanisms of action for dolutegravir (DTG) developmental toxicity. DESIGN: Folate receptor 1 (FOLR1) was examined as a target for DTG developmental toxicity using protein and cellular interaction studies and an animal model. METHODS: FOLR1 competitive binding studies were used to test DTG for FOLR1 antagonism. Human placenta cell line studies were used to test interactions with DTG, folate, and cations. Zebrafish were selected as an animal model to examine DTG-induced developmental toxicity and rescue strategies. RESULTS: FOLR1 binding studies indicate DTG is a noncompetitive FOLR1 antagonist at therapeutic concentrations. In-vitro testing indicates calcium (2âmmol/l) increases FOLR1-folate interactions and alters DTG-FOLR1-folate interactions and cytotoxicity. DTG does not inhibit downstream folate metabolism by dihydrofolate reductase. Early embryonic exposure to DTG is developmentally toxic in zebrafish, and supplemental folic acid can mitigate DTG developmental toxicity. CONCLUSION: Folates and FOLR1 are established modifiers of risk for neural tube defects, and binding data indicates DTG is a partial antagonist of FOLR1. Supplemental folate can ameliorate increased developmental toxicity due to DTG in zebrafish. The results from these studies are expected to inform and guide future animal models and clinical studies of DTG-based antiretroviral therapy in women of childbearing age.
Subject(s)
Folate Receptor 1/antagonists & inhibitors , Folic Acid/administration & dosage , Heterocyclic Compounds, 3-Ring/toxicity , Zebrafish Proteins/antagonists & inhibitors , Zebrafish/embryology , Animals , Cell Line , Dietary Supplements , Embryonic Development/drug effects , Female , Folate Receptor 1/genetics , HIV Infections/drug therapy , HIV Integrase Inhibitors/toxicity , Humans , Models, Animal , Oxazines , Piperazines , Pregnancy , Pyridones , Toxicity Tests , Zebrafish/genetics , Zebrafish Proteins/geneticsABSTRACT
The prevalence of diabetes mellitus has been incremented in the current century and the need for novel therapeutic compounds to treat this disease has been significantly increased. One of the most promising approaches is to inhibit intestinal alpha glucosidases. Based on our previous studies, four pyrimidine-fused heterocycles (PFH) were selected as they revealed satisfactory inhibitory action against mammalian α-glucosidase. The interaction of these compounds with both active domains of human maltase-glucoamylase (MGAM) and their effect on human Caco-2 cell line were investigated. The docking assessments suggested that binding properties of these ligands were almost similar to that of acarbose by establishing hydrogen bonds especially with Tyr1251 and Arg526 in both C-terminal and N-terminal MGAM, respectively. Also, these compounds indicated a stronger affinity for C-terminal of MGAM. L2 and L4 made tightly complexes with both terminals of MGAM which in turn revealed the importance of introducing pyrimidine scaffold and its hinge compartment. The results of molecular dynamics simulation analyses confirmed the docking data and showed deep penetration of L2 and L4 into the active site of MGAM. Based on cell cytotoxicity assessments, no significant cell death induction was observed. Hence, these functional MGAM inhibitors might be considered as new potential therapeutic compounds in treatment of diabetes and its complications.
Subject(s)
Glycoside Hydrolase Inhibitors/pharmacology , Pyrimidinones/pharmacology , alpha-Glucosidases/metabolism , Acarbose/chemistry , Caco-2 Cells , Catalytic Domain , Glycoside Hydrolase Inhibitors/chemistry , Glycoside Hydrolase Inhibitors/toxicity , Heterocyclic Compounds, 3-Ring/chemistry , Heterocyclic Compounds, 3-Ring/pharmacology , Heterocyclic Compounds, 3-Ring/toxicity , Humans , Hydrogen Bonding , Hydrophobic and Hydrophilic Interactions , Ligands , Molecular Docking Simulation , Molecular Dynamics Simulation , Molecular Structure , Pyrimidinones/chemistry , Pyrimidinones/toxicity , alpha-Glucosidases/chemistryABSTRACT
Simvastatin is an inhibitor of the 3-hydroxy-3-methylglutaryl-CoA reductase used for decreasing low density lipoprotein (LDL)-cholesterol in patients. It is well-tolerated but can cause myopathy. Our aims were to enlarge our knowledge regarding mechanisms and effects of insulin on simvastatin-associated myotoxicity in C2C12 myotubes. Simvastatin (10 µM) reduced membrane integrity and ATP content in myotubes treated for 24 hours, which could be prevented and partially reversed concentration- and time-dependently by insulin. Furthermore, simvastatin impaired the phosphorylation of Akt (Protein Kinase B) mainly at Ser473 and less at Thr308, indicating impaired activity of the mammalian Target of Rapamycin Complex 2 (mTORC2). Impaired activation of Akt increased mRNA expression of the muscle atrophy F-Box (MAFbx), decreased activation of the mammalian Target of Rapamycin Complex 1 (mTORC1) and stimulated apoptosis by impairing the Ser9 phosphorylation of glycogen synthase kinase 3ß. Decreased phosphorylation of Akt at both phosphorylation sites and of downstream substrates as well as apoptosis were prevented concentration-dependently by insulin. In addition, simvastatin caused accumulation of the insulin receptor ß-chain in the endoplasmic reticulum (ER) and increased cleavage of procaspase-12, indicating ER stress. Insulin reduced the expression of the insulin receptor ß-chain but increased procaspase-12 activation in the presence of simvastatin. In conclusion, simvastatin impaired activation of Akt Ser473 most likely as a consequence of reduced activity of mTORC2. Insulin could prevent the effects of simvastatin on the insulin signaling pathway and on apoptosis, but not on the endoplasmic reticulum (ER) stress induction.
Subject(s)
Insulin/pharmacology , Muscle Cells/drug effects , Muscle, Skeletal/drug effects , Simvastatin/toxicity , Animals , Cell Line , Endoplasmic Reticulum/drug effects , Endoplasmic Reticulum/metabolism , Heterocyclic Compounds, 3-Ring/toxicity , Mice , Muscle Fibers, Skeletal/drug effects , Muscle Fibers, Skeletal/metabolism , Muscle Proteins/metabolism , Muscle, Skeletal/cytology , Receptor, Insulin/metabolism , SKP Cullin F-Box Protein Ligases/metabolism , Simvastatin/antagonists & inhibitorsABSTRACT
An activated AKT pathway underlies the pathogenesis of soft tissue sarcoma (STS), with over-expressed phosphorylated AKT (p-AKT) correlating with a poor prognosis in a subset of STS cases. Recently, eribulin, a microtubule dynamics inhibitor, has demonstrated efficacy and is approved in patients with advanced/metastatic liposarcoma and breast cancer. However, mechanisms of eribulin resistance and/or insensitivity remain largely unknown. In this study, we demonstrated that an increased p-AKT level was associated with eribulin resistance in STS cells. We found a combination of eribulin with the AKT inhibitor, MK-2206, synergistically inhibited STS cell growth in vivo as well as in vitro. Mechanistically, eribulin plus MK-2206 induced G1 or G2/M arrest by down-regulating cyclin-dependent kinases, cyclins and cdc2, followed by caspase-dependent apoptosis in STS cells. Our findings demonstrate the significance of p-AKT signaling for eribulin-resistance in STS cells and provide a rationale for the development of an AKT inhibitor in combination with eribulin to treat patients with STS.
Subject(s)
Antineoplastic Agents/toxicity , Furans/toxicity , Heterocyclic Compounds, 3-Ring/toxicity , Ketones/toxicity , Protein Kinase Inhibitors/toxicity , Sarcoma/metabolism , Soft Tissue Neoplasms/metabolism , Animals , Apoptosis/drug effects , Cell Cycle Checkpoints , Cell Line , Cell Line, Tumor , Cyclin-Dependent Kinases/genetics , Cyclin-Dependent Kinases/metabolism , Cyclins/genetics , Cyclins/metabolism , Drug Synergism , Humans , Mice , Mice, Inbred BALB C , Proto-Oncogene Proteins c-akt/genetics , Proto-Oncogene Proteins c-akt/metabolismABSTRACT
The toxicity of insecticides is associated with a variety of factors including temperature, and global warming is bound to lead to the outbreak of pests; therefore, it is important to study the influence of temperature on insecticide toxicity and pest control. In this study, the influence of temperature on the toxicity of insecticides to Nilaparvata lugens (BPH) was determined. The results showed that the sensitivity of BPH to cycloxaprid (LC50â¯=â¯42.5-0.388â¯mg/L), nitenpyram (LC50â¯=â¯3.49-0.187â¯mg/L), triflumezopyrim (LC50â¯=â¯0.354-0.0533â¯mg/L) and chlorpyrifos (LC50â¯=â¯36.3-7.41â¯mg/L) increased significantly when the temperature changed from 18⯰C to 36⯰C. BPH sensitivity to etofenprox (LC50â¯=â¯9.04-54.2â¯mg/L) was also affected by temperature. Additionally, the feeding amount and the activities of three detoxification enzymes [cytochrome P450 (P450), glutathione S-transferase (GST) and carboxylesterase (CarE)] of BPH at different temperatures were also measured. The feeding amounts were positively correlated with temperature increases while the activities of P450 and GST were significantly inhibited. The correlation analysis showed that changes in P450 activity (but not GST activity) were closely related to the sensitivity of BPH to cycloxaprid, nitenpyram, chlorpyrifos, and etofenprox according to the variation in temperatures. This study provides a theoretical basis for the rational use of chemical pesticides under the global warming trend and provides a reference for the integrated management of BPH in the field.
Subject(s)
Hemiptera/drug effects , Insecticides/toxicity , Animals , Chlorpyrifos/toxicity , Cytochrome P-450 Enzyme System/metabolism , Heterocyclic Compounds, 3-Ring/toxicity , Insecticide Resistance , Neonicotinoids/toxicity , Pyridines/toxicity , TemperatureABSTRACT
Chemotherapeutic agents generally suffer from off-target cytotoxicity in noncancerous cell types, leading to undesired side effects. As a result, significant effort has been put into identifying compounds that are selective for cancerous over noncancerous cell types. Our laboratory has recently developed a series of near-infrared (NIR) fluorophores containing a phosphinate functionality at the bridging position of a xanthene scaffold, termed Nebraska Red (NR) fluorophores. Herein, we report the selective cytotoxicity of one NR derivative, NR744 , against HeLa (cervical cancer) cells versus NIH-3T3 (noncancerous fibroblast) cells. Mechanistic studies based on the NIR fluorescence signal of NR744 showed distinct subcellular localization in HeLa (mitochondrial) versus NIH-3T3 (lysosomal) that resulted from the elevated mitochondrial potential in HeLa cells. This study provides a new, NIR scaffold for the further development of reagents for targeted cancer therapy.
Subject(s)
Antineoplastic Agents/pharmacology , Apoptosis/drug effects , Fluorescent Dyes/pharmacology , Phosphinic Acids/pharmacology , Animals , Antineoplastic Agents/metabolism , Antineoplastic Agents/toxicity , Cell Line, Tumor , Cell Movement/drug effects , Fluorescent Dyes/metabolism , Fluorescent Dyes/toxicity , Heterocyclic Compounds, 3-Ring/metabolism , Heterocyclic Compounds, 3-Ring/pharmacology , Heterocyclic Compounds, 3-Ring/toxicity , Heterocyclic Compounds, 4 or More Rings/metabolism , Heterocyclic Compounds, 4 or More Rings/pharmacology , Heterocyclic Compounds, 4 or More Rings/toxicity , Humans , Mice , Microscopy, Confocal/methods , Microscopy, Fluorescence/methods , Mitochondria/metabolism , NIH 3T3 Cells , Phosphinic Acids/metabolism , Phosphinic Acids/toxicityABSTRACT
A series of novel furo[2,3-b]pyridine-2-carboxamide 4a-h/pyrido[3',2':4,5]furo[3,2-d] pyrimidin-4(3H)-one derivatives 5a-p were prepared from pyridin 2(1H) one 1 via selective O-alkylation with α-bromoethylester followed by cyclization, then reaction with different aliphatic primary amines to obtain 4 and further reaction with triethyl orthoacetate/triethyl orthoformate. Also prepared novel furo[2,3-b]pyridine-2-carbohydrazide Schiff's bases 7a-h and pyrido [3',2':4,5]furo[3,2-d]pyrimidin-4(3H)-one derivatives 8a-h starting from furo[2,3-b]pyridine carboxylate derivatives 3 by reaction with hydrazine hydrate to form 6 and reaction with diverse substituted aldehydes and cyclization. Products 4a-h, 5a-p, 7a-h and 8a-h were screened against four human cancer cell lines (HeLa, COLO205, Hep G2 and MCF 7) and one normal cell line (HEK 293). Compounds 4e, 4f, 4g, 5h, 7c, 7d, 7e and 7f showed significant anticancer activity against all the cell lines at micro molar concentration and found to be non-toxic to normal cell line. Studies for HeLa, COLO205 and MCF-7 using CoMFA and CoMSIA. Models from 3D-QSAR provided a strong basis for future rational design of more active and selective HeLa, COLO205 and MCF-7 cell line inhibitors.
Subject(s)
Antineoplastic Agents/pharmacology , Heterocyclic Compounds, 2-Ring/pharmacology , Heterocyclic Compounds, 3-Ring/pharmacology , Pyridines/pharmacology , Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/chemistry , Antineoplastic Agents/toxicity , Cell Line, Tumor , Cyclization , Drug Screening Assays, Antitumor , Furans/chemical synthesis , Furans/chemistry , Furans/pharmacology , Furans/toxicity , HEK293 Cells , Heterocyclic Compounds, 2-Ring/chemical synthesis , Heterocyclic Compounds, 2-Ring/chemistry , Heterocyclic Compounds, 2-Ring/toxicity , Heterocyclic Compounds, 3-Ring/chemical synthesis , Heterocyclic Compounds, 3-Ring/chemistry , Heterocyclic Compounds, 3-Ring/toxicity , Humans , Hydrogen Bonding , Molecular Structure , Pyridines/chemical synthesis , Pyridines/chemistry , Pyridines/toxicity , Pyrimidines/chemical synthesis , Pyrimidines/chemistry , Pyrimidines/pharmacology , Pyrimidines/toxicity , Quantitative Structure-Activity RelationshipABSTRACT
Cycloxaprid (CYC) is a novel neonicotinoid insecticide with high activity against resistant pests but is safe for mammals. The toxic effects of CYC on earthworms (Eisenia fetida) were studied in this paper. The 14-day exposure results showed that CYC is potentially toxic to earthworms, with a 14d-LC50 of 10.21 mg/kg dry soil, and that it induced tissue damage to the epidermis, gut, and neurochord at sublethal doses. During a 21-day exposure, CYC induced oxidative stress in earthworms, and both enzyme activities of catalase (CAT) and superoxide dismutase (SOD) were impacted. In addition, expression of the genes Cat and Sod were down- and upregulated, respectively. The activity of the enzyme acetylcholinesterase (AChE) was increased at day 7 but decreased at day 21 after CYC exposure, while expression of the signal transduction-related genes was significantly regulated. Our study shows for the first time that negative impacts could be induced by CYC on earthworms under both acute and chronic exposure through oxidative stress and gene regulation. The present study provides a database for assessing the environmental risk to non-target organisms resulting from the use of CYC.
Subject(s)
Heterocyclic Compounds, 3-Ring/toxicity , Insecticides/toxicity , Neonicotinoids/toxicity , Oligochaeta/drug effects , Pyridines/toxicity , Soil Pollutants/toxicity , Acetylcholinesterase/metabolism , Animals , Catalase/metabolism , Gene Expression Regulation/drug effects , Lethal Dose 50 , Oligochaeta/enzymology , Oligochaeta/genetics , Oxidative Stress/drug effects , Soil/chemistry , Superoxide Dismutase/metabolismABSTRACT
Heterocyclic amines (HCAs) are primarily produced during high temperature meat cooking. These compounds have been intensively investigated as mutagens and carcinogens. However, converging data suggest that HCAs may also be neurotoxic and potentially relevant to neurodegenerative diseases such as Parkinson's disease (PD). The identification of new potential etiological factors is important because most PD cases are sporadic. Our group previously showed that 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) was selectively neurotoxic to dopaminergic neurons. However, PhIP is one of many HCAs, a class of compounds that exhibits wide structural variability. The goal of this study was to determine the neurotoxicity of the most prevalent and best studied HCAs from three subclasses: aminoimidazoaazarenes (AIA), α-carbolines, and ß-carbolines. Using E17 rat primary midbrain cultures, we tested dopaminergic and non-dopaminergic neurotoxicity elicited by the following compounds: 2-amino-3-methylimidazo[4,5-f]quinoline (IQ), 2-amino-3,4-dimethylimidazo[4,5-f]quinoline (MeIQ), 2-amino-3,8-dimethylmidazo[4,5-f]quinoxaline (MeIQx), 2-amino-3,4,8-trimethylimidazo[4,5-f]quinoxaline (4,8-DiMeIQx), PhIP, 1-methyl-9H-pyrido[3,4-b]indole (harmane), 9H-pyrido[3,4-b]indole (norharmane) and 2-amino-9H-pyrido[2,3-b]indole (AαC) at concentrations ranging from 100â¯nM-5⯵M. All tested HCAs were selectively neurotoxic, though the dose required to elicit selective loss of dopaminergic neurons or decreases in dopaminergic neurite length was compound specific. Non-dopaminergic neurons were unaffected at all tested doses. The sensitivity (determined by threshold dose required to elicit selective neurotoxicity) appears to be unrelated to published mutagenic potency. Both AIA and α/ß-carbolines produced oxidative damage, which was magnified in dopaminergic neurons vs. non-dopaminergic neurons as further evidence of selective neurotoxicity. These studies are expected to prompt clinical and mechanistic studies on the potential role of HCA exposure in PD.